Day Two

• Exploring the development and application of fully humanised in vivo systems to replicate human immune responses and tumour biology, enabling robust evaluation of immunotherapies
• Demonstrating how this humanised model yielded clinically relevant data in diseases such as lymphoma and myeloma, with a focus on T cell engagers and co-stimulatory pathways
• Discussing how these models complement advanced in vitro systems and support decision-making across the drug development pipeline, from early efficacy to translational validation

• Development and application of organoids and PDX models to study adaptive responses to targeted therapies and immunotherapies in prostate cancer
• Elucidating which model from organoids and PDX mice is more representative of prostate cancer
• Using clinical data from Phase I and II trials to better understand mechanism of resistance and pathology to develop better therapeutic strategies with a focus on enhancing clinical relevance and therapeutic precision

• Discussing the limitations of cell-line derived xenograft models
• Deciphering Mode-of Action of ATACs in heterogenous patient-derived xenograft models
• Leveraging findings from the PDX model to better understand resistance mechanism of ADCs and ATACs

Witness some of the latest and greatest research in the tumour modelling field in this spotlight poster session! Visit the website for T&Cs for submitting a poster.

• Understanding the different tumour models used in drug discovery and development across the field
• Reiterating the importance of assessing animal welfare impact when selecting models, with strict parameters to ensure the science can be obtained without excessive animal burden
• Discussing how we can continue to incorporate the 3Rs into our workflows better

• Leveraging patient-derived organoids (PDOs) and genetically engineered mouse model (GEMM)-derived organoids to enhance the predictive power of cancer immunotherapy studies
• Overcoming technical and biological hurdles in the development of relevant advanced stage and metastatic mouse models to better mimic human disease progression
• Integrating experimental biology with computational modelling to align preclinical outputs with clinical datasets, facilitating the creation of predictive in silico frameworks for translational oncology

• Developing mathematical models to mechanistically describe pharmacokinetics/ pharmacodynamics observed in preclinical models
• Optimizing the translational approach for scaling between preclinical models and patients
• Uncovering the translational relevance and predictability of different preclinical models through a mathematical modelling approach

• Applying wt and humanised in vivo platforms to assess therapeutic performance of ADCC-inducing antibodies across solid and liquid tumour types, including CLL
• Identifying and validating biomarkers from head and neck cancer patient datasets, with correlation to preclinical mouse models
• Leveraging humanised mice to bridge mechanistic insights and clinical relevance, supporting the development of targeted immunotherapies with translational impact

• Highlighting the rationale behind selecting the model
• Identifying predictive biomarkers that correlate with drug response, aiding in patient stratification and personalised treatment
• Leveraging findings to empower dosing strategies and spotlighting future directions

The winning poster will be announced at this time. The winner will receive their award, and have their poster showcased on our website as a downloadable file.

• Spotlighting lessons learned taking a small molecule from discovery to the clinic and the types of models that were used
• Nurturing relationships with CROs and academic groups to leverage cancer-associated fibroblast (CAF) models and orthotopic models for preclinical studies
• Identifying biomarkers that can predict response to Wnt, aiding in patient stratification and the design of clinical trials

• Addressing the limitations of traditional mouse models for gamma-delta T cell studies and strategies for identifying or developing humanised mouse models
• Optimising experimental variables—such as cell source, transfer method, and tumour type—to align with specific therapeutic objectives, from efficacy assessment to immune profiling
• Implementing robust, foundational assays to evaluate gamma-delta T cell presence and activity following therapeutics, ensuring reliable data generation and efficient model characterisation

• Highlighting the background of fibroblast activation protein (FAP)-enabled pre|CISION®-peptide drug conjugates (PDCs) and the rationale for model selection
• Sharing best practices for developing co-cultures of tumour cells and human primary FAP+ fibroblasts to assess bystander activity of PDCs in physiologically relevant systems
• Characterising PDCs using CDX, PDX models, and spheroid co-cultures to better understand their mechanism of action